Natpara (rhPTH [1-84]) is currently under review by the U.S. Food and Drug Administration for the treatment of patients with hypoparathyroidism. Originally, the Prescription Drug User Fee Act (PDUFA) date was set for October 24, 2014 but that has been moved to January 24, 2014. In this exclusive interview with Francois Nader, MD, MBA, president, chief executive officer, and director of NPS Pharmaceuticals, Dr Nader provides an update on Natpara in both the United States and Europe (where it is called Natpar).
Natpara is a bioengineered replacement therapy for endogenous parathyroid hormone (PTH) for the treatment of hypoparathyroidism.
For more information about the company and Natpara, visit www.npsp.com